- The Wall Street Journal•56 minutes ago
GlaxoSmithKline is pinning the future of its HIV business on an audacious bet: upending the decades-old triple-drug treatment strategy that has turned a fatal illness into a chronic condition.
Biotech is one of the sectors where M&A activities never stop, as the potential for growth and development is immense. After the termination of a $160 billion merger with Allergan plc Ordinary Shares (NYSE: ...
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||34.82 x 100|
|Ask||34.86 x 300|
|Day's Range||34.66 - 35.10|
|52wk Range||28.25 - 37.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||30.87|
|Avg Vol (3m)||22,033,106|
|Dividend & Yield||1.20 (3.45%)|